- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06683274
Bascom Cleft Lift for Primary Wound Healing in Complex and Recurrent Sacrococcygeal Pilonidal Sinus Disease (BATCRAC)
The goal of this observational study is to improve care for patients with complex or recurrent pilonidal sinus disease by developing and implementing a best practice care pathway, including a standardized cleft lift operation.
The main question it aims to answer is: Does a best practice care pathway with standardized cleft lift operation lead to shorter wound healing time and time to return to normal activities, compared to current standard care, with traditional excision techniques.
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Max Goudberg, MD
- Phone Number: +31622577653
- Email: m.r.goudberg@asz.nl
Study Locations
-
-
-
Dordrecht, Netherlands, 3318AT
- Recruiting
- Albert Schweitzer ziekenhuis
-
Contact:
- Max Goudberg
- Phone Number: +31622577653
- Email: m.r.goudberg@asz.nl
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- 16 years of age and older
- Symptomatic complex or recurrent pilonidal sinus disease
- Planned for surgical treatment
- Signed informed consent
Exclusion Criteria:
- Pregnant
- Insufficient understanding of the Dutch language or otherwise unable to give consent
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Control cohort
Current practice cohort
|
|
Interventional cohort
Best practice care pathway with standardized Bascom cleft lift
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Wound healing time
Time Frame: The outcome will be evaluated at each follow-up visit, at 1-3 weeks, 4-6 weeks and 6 months postoperative. If necessary, additional visits will be planned
|
Time to wound healing (in days), this will be self reported by patients when the skin is completely closed, and will be validated through clinical assessment by the surgeon.
|
The outcome will be evaluated at each follow-up visit, at 1-3 weeks, 4-6 weeks and 6 months postoperative. If necessary, additional visits will be planned
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Return to normal activities
Time Frame: The outcome will be evaluated at each follow-up visit, at 1-3 weeks, 4-6 weeks and 6 months postoperative. If necessary, additional visits will be planned
|
Time to return to normal activities after surgery (in days).
This will be self reported by patients through a brief checklist on which the activities (washing, dressing, sitting, work/study) should be checked when possible without discomfort.
|
The outcome will be evaluated at each follow-up visit, at 1-3 weeks, 4-6 weeks and 6 months postoperative. If necessary, additional visits will be planned
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quality of Life
Time Frame: Baseline, 4-6 weeks and 6 months postoperative.
|
Quality of Life, measured with EuroQol 5 dimensions, 5 levels (EQ-5D-5L) questionnaire.
The questions are answered on a 5 point Likert scale.
Ranging from 5-25, with 5 being the best possible outcome and 25 being the worst possible outcome.
Additionally, there is a general question on a 0-100 scale, with 0 being the worst health possible and 100 being the best health possible.
|
Baseline, 4-6 weeks and 6 months postoperative.
|
|
Pain
Time Frame: The outcome will be evaluated at each follow-up visit, at 1-3 weeks, 4-6 weeks and 6 months postoperative.
|
Pain score, on a Numeric Rating Scale ranging from 0-10 with 0 representing 'no pain' and 10 representing 'the worst pain possible'
|
The outcome will be evaluated at each follow-up visit, at 1-3 weeks, 4-6 weeks and 6 months postoperative.
|
Collaborators and Investigators
Investigators
- Principal Investigator: Robert Smeenk, MD, PhD, Albert Schweitzer Ziekenhuis, Netherlands
- Principal Investigator: Boudewijn Toorenvliet, MD, PhD, Ikazia Ziekenhuis
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2024.077 (Other Identifier: ASz)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.